Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » US Appeals Court Lifts Injunction on 10x Genomics' Linked-Reads, Single-Cell CNV Assays

US Appeals Court Lifts Injunction on 10x Genomics' Linked-Reads, Single-Cell CNV Assays

Aug 03, 2020
|
staff reporter

This story has been updated to include comments from Bio-Rad Laboratories.

NEW YORK – A US appeals court has lifted a permanent injunction against two products from 10x Genomics that a jury had found infringed patents held by Bio-Rad Laboratories: the Chromium Single-Cell CNV Solution and the discontinued Linked-Reads assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Another Protocol Released

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

From Just Some Blood

Time magazine looks into how liquid biopsies are changing cancer care.

Numerous Countries Agree to Vaccine Plan

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

PNAS Papers on Hypertrophic Cardiomyopathy, Major Depression, Spanish SARS-CoV-2 Cat

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

What's Popular?

In Business News

  1. Illumina to Acquire Grail for $8B in Cash and Stock

  2. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  3. Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark

  4. Arna Genomics Raises $3.5M In Series A Financing

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.